Multiple myeloma treatment and management in the elderly
1Pharmaceutical Management Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Abstract:
More than 60% of Americans with multiple myeloma are older than 65 years of age, and the number of new patients is expected to double by 2030. In addition to this anticipated increase, most patients have advanced disease at diagnosis and require some level of intervention. During the past 10 years, standard care has advanced from chemotherapy and autologous stem-cell transplant to newer targeted agents, introducing the proteasome inhibitors and immunomodulatory agents to the myeloma armamentarium. Myeloma patients live longer because of these novel treatments and better supportive care measures. However, improved disease control comes with new toxicities, and treatment choices need to be balanced with quality of life. Recent clinical trials studied elderly cohorts, and the results can help with geriatric treatment decisions. Expert consensus guidelines and limited trial results in frail individuals provide dose-reduction and monitoring strategies for geriatric practitioners. Ultimately, each patient's physical limitations and vulnerabilities determine optimal myeloma management, and a comprehensive geriatric assessment assists with this aim.
More Related Videos
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Related Concept Videos
Drug Dosing: Geriatric Patients
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Pharmacodynamics in Geriatric Patients: Effects of Age
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
